Highlights
- 1Nature · 2024
- 2Cancer research · 2023
- 3British journal of cancer · 2022
Publications
Funding
Active
15 grants- Sub-PIR01CA307511-01Intratumor heterogeneity as a correlate of clinical outcome in patients avoiding radical cystectomyNational Cancer Institute · 2026–2031 · via Fox Chase Cancer Center Medical Group Inc.
- PIRSG-25-1511719-01-ETGermline-somatic interactions as drivers and therapeutic targets in bladder cancerAmerican Cancer Society · 2026–2030
- PIR37CA279737-04Targeting APOBEC3A-induced genetic heterogeneity and drug resistance in bladder cancerNational Cancer Institute · 2023–2028
- KPBCAN 1659349Targeting APOBEC3A-driven transcriptional reprogramming to prevent metastasis in bladder cancerBladder Cancer Advocacy Network, Inc. · 2026–2028
- KPBCAN 1660936Environmental Polycyclic Aromatic Hydrocarbon Exposure Drives APOBEC3-Mediated Mutagenesis and Bladder CarcinogenesisBladder Cancer Advocacy Network, Inc. · 2026–2028
- PIAHA 265315-01Epigenetic Erasure of Mechanical Memory to Reverse Persistent Cardiac FibrosisAmerican Heart Association · 2026–2028Fellowship
- Co-IR01CA276506-01A1An urinary drug disposing approach for treatment of bladder CancerNational Cancer Institute · 2023–2028
- PISRA 254792-01Modeling Imetelstat Response in Bladder Cancer Organoid and PDX ModelsGeron Corporation · 2025–2027Contract
- MPIUL1TR002384-06Clinical and Translational Science Center - UL1National Center for Advancing Translational Sciences · 2022–2027
- PIBCAN 241712-02Bio-Digital Avatars for Personalized Sequencing of Bladder Cancer TherapiesBladder Cancer Advocacy Network, Inc. · 2024–2027
- PI1545601Targeting cytidine deaminase-induced chromosomal instability as a driver of metastasis in bladder cancerBladder Cancer Advocacy Network, Inc. · 2025–2026
- PI25-80-85-FALTCharacterization of CDADC1, a Putative CTP Deaminase Co-deleted with RB1 in Bladder CancerAmerican Association for Cancer Research · 2025–2026
- Sub-PIU01CA260369-05Optimization Of Urinary DNA Deep Sequencing Tests To Enhance Clinical Staging Of Bladder Cancer PatientsNational Cancer Institute · 2021–2026 · via Fox Chase Cancer Center Medical Group Inc.
- PICAT-24-1413358-01-CATGermline-somatic interactions as drivers and therapeutic targets in bladder cancerAmerican Cancer Society · 2025–2025
- PII16-0054Targeting cytidine deaminase-induced chromosomal instability as a driver of metastasis in bladder cancerStarr Cancer Consortium · 2023–2025
Completed grants (13)
- PIHT9425-23-1-0790Targeting APOBEC3A-induced chromosomal instability as a driver of metastasis in bladder cancerU.S. Department of Defense · 2023–2025
- KPHT9425-24-1-0798Targeting ecDNA to reverse therapy-resistance in urothelial cancer.U.S. Department of Defense · 2024–2025
- PII14-0047Defining The Functional Impact Of Composite Mutations In Oncogene-Driven Urothelial Cancer Using Circulating-Tumor Dna And Single-Cell SequencingStarr Cancer Consortium · 2021–2024
- PINYGC 211592-02Immunogenomic determinants of ethnic disparities in clinical outcomes for urothelial cancer patientsNew York Genome Center Inc. · 2020–2024
- KPBCAN 223355-01Synthetic lethal strategies to limit tumor evolution driven by APOBEC3 activity in urothelial cancerBladder Cancer Advocacy Network, Inc. · 2022–2023
- PIAddgene 699808Addgene 699808Addgene, Inc. · 2022–2023
- PILAA 223379-01A germline registry and biorepository of patients with urothelial cancerThe Leo & Anne Albert Institute for Bladder Cancer Care and Research · 2022–2023
- PII12-0030APOBEC MUTAGENESIS IN BLADDER CANCER: MECHANISMS AND THERAPEUTIC OPPORTUNITIESStarr Cancer Consortium · 2019–2021
- PIW81XWH-17-1-0539Dissecting the Role of APOBEC3 Mutagenic Proteins as Drivers of Genomic-Instability and Chemotherapy-Resistance in Urothelial CarcinomaU.S. Department of Defense · 2017–2021
- KPASCO 192251-01Dissecting the role of co-occurring FGFR and cell cycle genomic alterations in sensitivity of urothelial carcinoma (UC) to combined FGFR- and CDK4/6-inhibitionThe Asco Cancer Foundation · 2019–2020
- MPIP50CA221745-02SPORE in Bladder CancerNational Cancer Institute · 2018–2020 · via Sloan-Kettering Institute for Cancer Research
- PISRA 192530-01Weill Cornell to support the Functional Genomics Initiative (FGI)Memorial Sloan Kettering Cancer Center · 2019–2019Contract
- MPISRA 193583-01Weill Cornell to support the Functional Genomics Initiative (FGI)Memorial Sloan Kettering Cancer Center · 2019–2019Contract
Clinical research
Active
1 study- PIGermline-somatic interactions as drivers and therapeutic targets in bladder cancerWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
News mentions
- American Cancer Society Grant to Fund Research on Urinary Tract Cancer TherapiesApril 7, 2026
A $1 million Research Scholar Grant from the American Cancer Society will help a multi-institution team led by Dr. Bishoy Faltas, associate professor of medicine at Weill Cornell Medicine, to develop new therapy combinations for hard-to-treat urinary tract cancers.
- AI Meets Oncology: New Model Personalizes Bladder Cancer TreatmentMarch 28, 2025
Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more effective model for predicting how patients with muscle-invasive bladder cancer will respond to chemotherapy.
- Awards & Honors: February 2024February 29, 2024
Awards, honors and achievements for the month of February.
- Awards & Honors: December 2023December 29, 2023
Awards, honors and achievements for the month of December.
- Bishoy M. Faltas Receives Prestigious MERIT GrantNovember 21, 2023
Dr. Bishoy M. Faltas, the Gellert Family-John P. Leonard, M.D. Research Scholar and an assistant professor of medicine at Weill Cornell Medicine, has been awarded a $4 million, seven-year MERIT grant from the National Cancer Institute (NCI) at the National Institutes of Health (NIH).
Show 4 more mentions
- Enzyme That Protects Against Viruses Could Fuel Cancer EvolutionDecember 28, 2022
An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells.
- Three Weill Cornell Medicine Faculty Win ASCI Young Physician-Scientist AwardsMarch 3, 2022
Three Weill Cornell Medicine faculty members have received Young Physician-Scientist Awards from the American Society for Clinical Investigation. The 2022 award recipients are Drs. Bishoy M. Faltas, Gunisha Kaur and Hasina Outtz Reed.
- Germline Whole-Exome Sequencing Reveals Potential New Treatment Opportunities in Bladder CancersDecember 8, 2020
A significant percentage of patients with urothelial cancers have inherited gene variants that drive the progression of these cancers, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
- Distinctive Biology Drives New Therapies in Upper Urinary Tract CancersJuly 9, 2019
A newly available drug may improve the effectiveness of immunotherapy in hard-to-treat cancers of the upper urinary tract, suggests a study published by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Mentoring
MD · 1
- LGLilly GuMD mentee · Class of 2023
External relationships
Advisory/Scientific Board Member
Bladder Cancer Advocacy Network, Inc. · One Biosciences SAS
Other Interest
Guardant Health, Inc.
Other
UroToday